In the final stage, heart-failure symptoms appear— coughing, shortness of breath, weight loss and fainting— and treatment becomes necessary, though prognosis is often poor. People generally live longer thanks to more treatment options and advanced supportive care: around 40 % of human patients die within 10 years of diagnosis, while dogs vary widely, some living 6 – 12 months and others suffering sudden death within weeks.
Treatment in people and dogs
In humans, treatment aims to minimise the effects of heart failure and delay progression. ACE inhibitors relax blood vessels to reduce the heart’ s workload; β-blockers slow the heart rate, lower stress hormones and improve efficiency; diuretics clear excess fluid, easing lung congestion, leg swelling and breathlessness. In later stages, inotropic agents help the heart pump more effectively and can steady the rhythm— usually short-term and hospital-based, used when the heart can no longer pump adequately on its own.
Canine treatment is similar: ACE inhibitors and diuretics are both used, though β-blockers are less common( reserved for arrhythmias rather than all cases), and inotropic agents are given earlier, from the start of heart failure, to improve contractility and cardiac output. Heart transplants are a last resort in humans; in dogs, transplants and cardiac assist devices are generally unavailable. One human-only option is the implantable cardioverter defibrillator, a small battery-powered device implanted in the chest that monitors rhythm and delivers electrical therapy to stop life-threatening arrhythmias.
Breeds, variants and genetics
Although any dog can develop DCM, some breeds are especially affected— Dobermanns, St Bernards, Newfoundlands, Great Danes, Irish Wolfhounds, Boxers and English Cocker Spaniels. Canine DCM has two histopathological variants, defined by how the heart tissue looks under the microscope and therefore not diagnosable in living dogs.
The more common“ attenuated wavy fibre” type shows thin, irregular muscle and a loss of normal mass, as impaired contractility causes the muscle to atrophy under constant stress. The“ fatty infiltration” type, associated with Dobermanns, Boxers and Great Danes, sees fat cells invade between muscle fibres— these breeds have a genetic predisposition and a high risk of arrhythmias and sudden death.
In humans, a single copy of a disease-causing gene can raise the risk of DCM, and those with an affected parent are more predisposed; the disease can also be autosomal recessive( needing two copies), X-linked( more severe in males), or mitochondrial. Because mitochondria carry their own DNA inherited only from the mother, only mothers pass on mitochondrial DCM; abnormal mitochondrial DNA reduces ATP production, leaving the heart muscle unable to contract effectively and more vulnerable to damage. In both dogs and humans, individuals can carry DCM-linked genes without developing the disease— a phenomenon called reduced penetrance, where the gene weakens the heart but additional genetic or environmental factors are needed to tip into full disease.
Conclusion
Dilated cardiomyopathy can be devastating, but studying it across humans and dogs has revealed how tightly heart structure, genetics and environment are linked. By understanding the mechanisms that weaken the heart— from genetic mutations to long-term stress responses— scientists can better prevent, detect and manage the disease. As research continues, the shared biology between species may yield insights that benefit both human and veterinary medicine.
References
01 Comparative review of dilated cardiomyopathy in humans and dogs, covering clinical staging, neurohormonal activation( SNS and RAAS), treatment strategies, breed predisposition and the genetics of inherited DCM.
CATALYST 18